Microbix Biosystems (TSE:MBX) Director Martin Marino Acquires 69,000 Shares

Microbix Biosystems Inc. (TSE:MBX) Director Martin Marino bought 69,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was purchased at an average cost of C$0.26 per share, for a total transaction of C$17,940.00. Following the completion of the transaction, the director directly owned 1,860,667 shares in the company, valued at approximately C$483,773.42. This trade represents a 3.85% increase in their position.

Martin Marino also recently made the following trade(s):

• On Thursday, May 28th, Martin Marino bought 115,000 shares of Microbix Biosystems stock. The stock was purchased at an average cost of C$0.28 per share, for a total transaction of C$32,200.00.
• On Wednesday, May 27th, Martin Marino bought 24,500 shares of Microbix Biosystems stock. The stock was purchased at an average cost of C$0.26 per share, for a total transaction of C$6,370.00.

Microbix Biosystems Trading Down 1.8%

Shares of MBX opened at C$0.28 on Friday. The company has a current ratio of 5.35, a quick ratio of 5.57 and a debt-to-equity ratio of 27.03. The firm has a market capitalization of C$37.81 million, a P/E ratio of -6.71 and a beta of 0.48. The stock’s fifty day simple moving average is C$0.24 and its 200 day simple moving average is C$0.24. Microbix Biosystems Inc. has a twelve month low of C$0.21 and a twelve month high of C$0.34.

Microbix Biosystems (TSE:MBX) last issued its earnings results on Thursday, May 14th. The company reported C($0.01) earnings per share for the quarter. The firm had revenue of C$3.38 million during the quarter. Microbix Biosystems had a negative return on equity of 21.02% and a negative net margin of 38.62%. On average, equities research analysts forecast that Microbix Biosystems Inc. will post 0.02 earnings per share for the current year.

About Microbix Biosystems

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.